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Abstract
Background: The development and validation study of the Clinical Chronic Obstructive Disease
(COPD) Questionnaire (CCQ) has recently been published in this journal. The CCQ is the first
questionnaire that incorporates both clinician and patient guideline goals in the clinical control
evaluation of patients with COPD in general clinical practice. The aim of this study is the validation
of the CCQ questionnaire in Italian, in specific pulmonary disease clinical practice.
Methods: Validity was tested on a population of healthy subjects and patients with COPD, using
the Italian validated version of the Short Form Health Survey (SF-36) and guideline recommended
routine measurement in COPD patients (FEV1, FVC, BMI and functional dyspnoea). Test-retest
reliability was tested by re-administering the CCQ after 2 weeks. Responsiveness was tested by re-
administering the CCQ after three weeks of hospital pulmonary rehabilitation. Distance walked
and Borg breathlessness rating were measured at the end of the six-minute walking test (6 MWT),
before and after rehabilitation.
Results: Cross-sectional data were collected from 175 subjects (55 healthy; 40 mild-moderate, 50
severe and 25 very severe COPD). Cronbach's alpha was high (0.89). The CCQ scores in patients
were significantly worse than in healthy subjects. The CCQ total score in patients with COPD was
significantly worse in those with BMI < = 21. Significant correlations were found between the CCQ
total score and domains of the SF-36 (rho = -0.43 to rho = -0.72). The correlation between the
CCQ and FEV1 % predicted was rho = -0.57. The correlation between the CCQ and MRC was
rho = 0.63. Test-retest reliability was determined in 112 subjects over a period of two weeks (Intra
Class Coefficient = 0.99). Forty-six patients with COPD showed significant improvement in CCQ
scores, distance-walked and Borg breathlessness rating after 3 weeks of pulmonary rehabilitation,
indicating CCQ responsiveness.
Conclusions: The CCQ is self-administered and has been specially developed to measure clinical
control in patients with COPD. Data support its validity, reliability and responsiveness in Italian and
in specific pulmonary disease clinical practice.
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Background
The American Thoracic Society (ATS) and European Res-
piratory Society (ERS) have jointly proposed standards [1]
for the diagnosis, treatment and spirometric classification
of patients with chronic obstructive pulmonary disease
(COPD). According to the GOLD (Global Obstructive
Lung Disease) guideline [2], the goals of clinical control in
patients with COPD include health-related quality of life
goals (improved exercise tolerance and emotional func-
tion) and clinical goals (prevention of disease progression
and minimization of symptoms).
The Clinical COPD questionnaire (CCQ) [3] is the first
practical clinical instrument to be used for routine evalu-
ation of clinical control (symptom, functional state and
mental state) concerning patients with COPD, in general
practice. The development and validation study has been
published in this journal and data were collected from
119 subjects. The aim of the present study is the validation
of the CCQ in Italian in specific pulmonary disease clini-
cal practice. In this practice, the ATS/ERS [1] recom-
mended routine measurements, in all patients with
COPD, are the following: forced expiratory volume in one
second (FEV1) and forced vital capacity (FVC), body mass
index (BMI) and functional dyspnoea (Medical Research
Council – MRC).
Methods
Subjects
Healthy subjects were selected in social meeting places.
Subjects were asked, individually, to answer a simple
questionnaire after the study had been explained to them.
Only subjects over 40 years of age were interviewed. We
excluded subjects with any disease symptoms, or any lim-
itation in daily activities for any reason, or who men-
tioned suffering from disabling chronic diseases (COPD,
asthma, arthritis, angina or heart insufficiency). All sub-
jects gave their informed written consent for baseline
spirometry and questionnaires administration, as
approved by the local Medical Ethics Committee. We
enrolled 55 subjects, 52 non-smokers and 3 ex-smokers.
Subject data are shown in Table 1.
Patients with COPD were consecutively enrolled in the
outpatient section of our Division during medical consul-
tation. According to the guidelines [1,2], COPD was
defined by the presence of chronic cough, sputum produc-
tion and/or dyspnoea. Patients with airways obstruction
(FEV1/FVC <= 0.70) were classified as mild (FEV1 post-
bronchodilator (pb) >= 80% predicted), moderate (FEV1
pb >= 50% predicted), severe (FEV1 pb >= 30% predicted)
and very severe (FEV1 pb < 30% predicted). We excluded
COPD patients with: a) significant improvement of FEV1
pb (>= 15 % and/or 200 ml) compared with baseline, b)
disease exacerbation in the previous four weeks, c)
asthma, chronic heart failure, obstructive sleep apnoea
syndrome, cancer or other disabling diseases except
COPD. We enrolled 120 patients (77 ex-smokers, 19
smokers). In 1999, the local health service authority
approved the standard evaluation procedures used in our
outpatient clinic for patients with COPD. The patients'
data are shown in Table 1.
Table 1: Characteristics and results of the study population in subgroups
Healthy subjects Mild-moderate COPD-
class I-II
Severe COPD-class III Very severe COPD-
class IV
N 5 54 05 52 5
Males (%) 62.0 85.0 63.6 72.0
Age (yr) 70abcd (41–82) 72abcd (58–84) 71abcd (41–86) 71abcd (42–86)
LTOT (%) 0.0 0.0 32.7 72.0
HMV (%) 0.0 0.0 7.2 8.0
BMI (kg/m2)2 5 . 7 abcd (18.0–30.0) 26.7abcd (18.6–37.8) 25.1abcd (16.4–36.4) 26.6abcd (16.2–34.6)
FEV1/FVC (%) 79.2 (70.4–94.5) 59.7 (40.4–68.2) 44.2 (27.9–66.2) 35.1 (21.1–57.3)
FEV1 (% predicted) 108.0 (69–132) 69.5 (51.4–117.1) 40.7 (30.2–49.8) 26.4 (16.4–29.7)
MRC functional dyspnoea 0.6 ± 3.4 (0–1) 1.1 ± 0.8 (0–2) 1.6 ± 0.7 (0–4) 2.3 ± 0.9 (0–4)
CCQ symptom 0.5 (0.0–4.0) 1.3b (0.0–4.0) 1.5b (0.3–5.8) 2.5 (0.3–3.8)
CCQ functional state 0.5a (0.0–5.3) 1.0a (0.0–3.5) 1.5 (0.0–5.3) 3.0 (0.3–5.0)
CCQ mental state 0.0 (0.0–4.5) 0.0 (0.0–5.0) 1.0c (0.0–6.0) 1.5c (0.0–6.0)
CCQ total 0.4 (0.0–3.8) 0.9 (0.0–3.5) 1.4 (0.3–5.2) 2.6 (0.4–4.3)
CCQ = Clinical COPD Questionnaire; range 0–6; 0 indicating best possible control and 6 indicating worst clinical control. LTOT = long term 
oxygen therapy. HMV = home assisted mechanical ventilation during night. BMI = body mass index. FVC = forced vital capacity. FEV1 = forced 
expired volume in one second. MRC = Medical Research Council. Healthy: normal spirometry, no chronic symptoms (cough, sputum production 
and/or dyspnoea). COPD classification by post-bronchodilator spirometry according to GOLD guidelines: mild-moderate FEV1/FVC <= 0.70 and 
FEV1 >= 50% predicted, severe FEV1/FVC <= 0.70 and FEV1 >= 30% predicted, very-severe FEV1/FVC <= 0.70 and FEV1 < 30% predicted. Medians 
not sharing a common superscript (a,b,c,d) are significantly different at p < 0.05 after Mann-Wittney U test.
MRC data are reported as mean value with standard deviation and range.Health and Quality of Life Outcomes 2005, 3:9 http://www.hqlo.com/content/3/1/9
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Forty-six patients with COPD (exclusion criteria as men-
tioned above) were enrolled in a continuous pulmonary
rehabilitation program, 31 males, 30 ex-smokers, 6 smok-
ers, 13 in long-term oxygen therapy (LTOT), 2 in home-
assisted mechanical ventilation during the night (HMV),
median age 72 (range 41–83), median FEV1 pb 46 % pre-
dicted (range 18–68). In 1999, the local health service
authority approved our continuous pulmonary rehab pro-
gram for patients with COPD.
Cross sectional validity
The CCQ was administered to all subjects. They were
instructed to recall their experiences during the previous
week. The CCQ is self-administered and contains only 10
items, subdivided into three domains: symptom (item 1–
2–5–6), functional state (item 7–8–9–10) and mental
state (item 3–4). Subjects responded to each question
using a 7 point scale from 0 = asymptomatic or no-limita-
tion, to 6 = extremely symptomatic or totally limited. The
overall clinical COPD control score and the score of the
three domains was calculated by adding all the scores
together and dividing the sum by the number of ques-
tions. The Italian translation of the copyrighted question-
naire and permission for use was obtained from T. van der
Molen [3] in February 2004 by one of the team (SD).
Lung function (FEV1 and FVC) was measured according
to ERS guidelines [4] using a portable turbine spirometer
(Pony, Cosmed, Italy) in base condition (all subjects) and
20 minutes after metered inhalation of 200 mcg of salb-
utamol (COPD patients only).
The copyrighted Italian validated version [5] of the 36-
item Short Form Health Survey (SF-36) [6], a generic
health-related quality of life questionnaire, was adminis-
tered to 120 patients with COPD and 55 healthy subjects.
The validated Italian version of SF-36 and permission for
use was obtained from GlaxoSmithKline in June 2002 by
one of the team (SP). Functional dyspnoea was assessed in
all subjects using the Medical Research Council (MRC)
scale as proposed by ATS/ERS guidelines [1]: 0 = not sub-
ject to breathlessness except with strenuous exercise, 1 =
subject to shortness of breath when hurrying or walking
up a gradually sloping hill, 2 = walks slower than people
of the same age due to breathlessness or has to stop for
breath when walking at a normal pace on a level, 3 = stops
for breath after walking about 100 m or after a few min-
utes on a level, 4 = too breathless to leave the house or
breathless when dressing or undressing. BMI was calcu-
lated by dividing weight (in kg) over height (in m2), for all
subjects.
Longitudinal validity
The CCQ was re-administered after 2 weeks (where there
was no variation of the previous therapy or introduction
of new therapy) in 112 subjects (53 healthy and 59
patients with COPD), 75 males, median age 71 years
(range 41–84), median FEV1 60 % predicted (range 19–
117). We tested the CCQ responsiveness in patients with
COPD undergoing continuous pulmonary rehabilitation.
Patients were treated in four successive groups in our hos-
pital following a standard three-week protocol. According
to guidelines [7], the program was individually tailored
and designed to optimize physical and social performance
and autonomy, and to be integrated into overall patient
treatment. It was a mix of physical retraining, thoracic and
general physiotherapy, education, self-monitoring. At the
end of the three-week hospitalization period, patients
received: a) their individual continuous pulmonary reha-
bilitation home program together with optimized phar-
macological therapy, b) the next three-month
appointment for the outpatient evaluation visit, c) the
next six-month appointment for successive inpatient
three-week pulmonary rehabilitation. The CCQ was
administered, on admission and on discharge from hospi-
tal, to 46 COPD patients. Patients were submitted to a 6-
minute walking test (6 MWT) on hospital admission and
discharge, according to guidelines [8]. In each occasion,
we measured distance-walked and breathlessness at the
end of 6 MWT, using the standard Borg rating scale [9].
This is a category scale in which simple verbal expressions,
that describe increasing degrees of breathlessness in exer-
cise, are linked to numbers (range from 0 = nothing at all
to 10 = maximal). The CCQ was also administered after
two more weeks during home-based comprehensive treat-
ment. All patients gave their informed written consent for
re-administration of CCQ, at home or in the outpatient
section.
Statistical Analysis
We applied the same analysis undertaken in the original
English validation study [3], taking for granted the same a
priori assumptions. Data analysis was performed using
SPSS version 12.0 (SPSS Inc, USA). Data are expressed as
median (range) unless otherwise stated. CCQ internal
consistency was evaluated by calculating Cronbach's
alpha coefficient (for the three domains and the total).
Non-parametrical testing (Mann-Whitney U test) was
used to determine the discriminant validity of the CCQ to
differentiate between healthy subjects and COPD patients
with different degrees of airways obstruction (mild, mod-
erate, severe, very severe). Spearman's rank correlations
were used to examine convergent and divergent validity.
Test-retest reliability analysis was done by calculating the
Intra-class Correlation Coefficient (ICC). Responsiveness
was tested using Wilcoxon U test. A value of p < 0.05 was
considered as statistically significant.Health and Quality of Life Outcomes 2005, 3:9 http://www.hqlo.com/content/3/1/9
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Results
Score distributions
The distributions for all domains and the overall scores
were skewed. In the population study, 12 subjects (7%)
scored optimally (= 0) in the total score, whereas 87 sub-
jects (50%) scored optimally in the mental state domain.
In the COPD group (120 subjects), 3% of the patients
scored optimally in the total score, whereas 35% scored
optimally in the mental state.
Internal consistency
Cronbach's alpha was 0.89 for the total score. Internal
consistencies of symptom, functional state and mental
state were 0.71, 0.88 and 0.80, respectively.
Discriminant validity
Healthy subjects had significantly lower (better) CCQ
score only in the symptom domain (p = 0,05) compared
with the small number (6 subjects) of patients with mild
COPD (FEV1 pb >= 80% predicted). At the same time, this
small group did not differ significantly (all CCQ scores)
from the group (34 patients) with moderate COPD (FEV1
pb < 80% and >= 50% predicted). For this reason, Table 1
shows CCQ scores in subgroups of healthy, mild-moder-
ate COPD, severe COPD, and very severe COPD subjects.
Healthy subjects had significantly lower CCQ scores than
patients with mild-moderate COPD with respect to total
score (p = 0.001), symptom domain (p = 0.000), mental
state domain (p = 0.005), except functional state domain.
Patients with mild-moderate COPD had better CCQ val-
ues compared with patients with severe COPD, with
respect to total score (p = 0.041), functional state (p =
0.017), mental state (p = 0.037), except symptom
domain. Patients with severe COPD had lower CCQ
scores than patients with very severe COPD, with respect
to total score (p = 0.007), functional state domain (p =
0.003), symptom domain (p = 0.032) except mental state
domain.
The healthy subjects group had a significantly (p = 0.003)
lower (better) MRC score than patients with mild-moder-
ate COPD. Patients with severe COPD had a significantly
(p = 0.003) higher (worse) MRC score than patients with
mild-moderate COPD. Patients with very severe COPD
had a significantly (p = 0.000) worse MRC score com-
pared with those with severe COPD (Table 1).
We did not find (Table 1) any significant difference in
BMI between healthy and diseased subjects and among
patients with increasing airways obstruction. In agree-
ment with Celli BR et al. [10], we considered 21 as a cut-
off BMI value for COPD patients' clinical control. Table 2
shows the data of 120 patients with COPD subdivided
into three different classes: subjects having BMI <= 21
(low-range), BMI <= 28 (acceptable-range) and BMI > 28
(high-range). In these three groups, no significant differ-
ence was found for FEV1 pb % predicted, age and MRC
score. CCQ scores were higher in both low and high BMI
groups, with respect to the acceptable BMI range group.
CCQ scores did not indicate any significant difference
between acceptable-range and high-range groups, except
in the CCQ mental state domain (p = 0.02). On the other
hand, there was a statistically significant difference
between low-range BMI and acceptable-range BMI groups
for CCQ total (p = 0.01), CCQ symptom (p = 0.01), CCQ
mental state (p = 0.04) except CCQ functional state.
Table 2: Characteristics and results of 120 patients in subgroups by BMI
BMI <= 21 BMI <= 28 BMI >28
N1 5 6 6 3 9
Males (%) 60.0 78.8 66.7
Age (yr) 71abc (42–86) 72abc (41–86) 71abc (50–82)
BMI (kg/m2) 19.7 (16.2–20.8) 25.0 (21.3–27.8) 29.9 (28.0–37.8)
FEV1/FVC (%) 39.0abc (21.1–64.8) 49.3abc (23.6–68.0) 50.3abc (27.5–68.2)
FEV1 (% predicted) 43.5abc (18.9–68.1) 44.5abc (19.5–117.1) 40.8abc (16.4–85.9)
MRC functional dyspnoea 1.8 ± 1.4abc (1–4) 1.4 ± 0.4abc (0–4) 1.7 ± 0.9abc (0–4)
CCQ symptom 2.5 (0.3–5.8) 1.3a (0.0–4.0) 1.5a (0.0–5.0)
CCQ functional state 2.3a (0.0–5.0) 1.3ab (0.0–5.3) 1.9ab (0.0–4.5)
CCQ mental state 2.0 (0.0–5.5) 0.5 (0.0–6.0) 1.5 (0.0–6.0)
CCQ total 2.2 (0.4–5.2) 1.2a (0.0–4.3) 1.7a (0.0–4.6)
BMI = body mass index. FVC = forced vital capacity. FEV1 = forced expired volume in one second. CCQ = Clinical COPD Questionnaire. MRC = 
Medical Research Council. Medians not sharing a common superscript (a,b,c) are significant different at p < 0.05 after Mann-Wittney U test.Health and Quality of Life Outcomes 2005, 3:9 http://www.hqlo.com/content/3/1/9
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Convergent and divergent validity
The CCQ score showed significant correlations with all
SF-36 components except the pain component(Table 3).
The CCQ scores and the FEV1 % predicted values corre-
lated significantly with respect to the whole population,
the highest correlation (Figure 1) being that of CCQ total
score (rho = -0.57; p < 0.01). The correlation (rho = -0.41)
was highly significant (p < 0.01) even if only the group of
120 COPD patients is considered.
The functional dyspnoea MRC score correlated strongly
with CCQ total (rho = 0.63), functional state (rho = 0,64),
symptom (rho = 0.52) and mental state (rho = 0.44).
No significant correlation was found between BMI and all
the CCQ scores.
Test-Retest Reliability and Responsiveness
The intra-class correlation coefficient was 0.99 for the
overall CCQ score.
In table 4 we see the results concerning responsiveness to
change of the CCQ, as tested in 46 COPD patients under-
going pulmonary rehabilitation. The group's CCQ scores
significantly (p = 0.000) improved after three weeks of
pulmonary rehabilitation in hospital. A statistically signif-
icant (p = 0.000) improvement was found also for walked
distance and Borg breathlessness rating at the end of 6
MWT. At the same time, no significant change was found
for the FEV1 pb %. After two successive weeks of individu-
alized home rehabilitation there was a worsening of CCQ
scores compared with the scores when hospital discharge
took place. Nevertheless, CCQ scores were still signifi-
cantly better than in baseline condition (hospital admis-
sion) for total (p = 0.01), functional state (p = 0.01),
symptom (p = 0.02) and mental state (p = 0.03).
Discussion
The validated Italian version of SF-36 was used as an
instrument to measure the convergent validity of the clin-
ical COPD questionnaire. Moderate to high correlations
were found in the present study supporting the conver-
gent validity in the Italian version, reflecting the original
English development and validation study [3]. FEV1 was
used to measure divergent validity with the same a priori
Table 3: Correlations between CCQ, SF-36, FEV1 and functional dyspnoea
CCQ Symptom CCQ Functional state CCQ Mental state CCQ Total
SF-36 Physical functioning -0.51** -0.78** -0.45** -0.72**
SF-36 Social functioning -0.36* -0.40** -0.40** -0.43**
SF-36 Role physical -0.34* -0.38** -0.43** -0.43**
SF-36 Role emotional -0.31* -0.30* -0.39* -0.36*
SF-36 Mental health -0.35* -0.47** -0.54** -0.48**
SF-36 Vitality -0.47** -0.58** -0.44** -0.57**
SF-36 Pain -0.15 -0.23 -0.05 -0.20
SF-36 Health perceptions -0.56** -0.58** -0.49** -0.64**
MRC functional dyspnoea +0.52** +0.64** +0.44** +0.63**
FEV1 (% predicted) -0.51** -0.50** -0.51** -0.57**
SF-36 = Medical Outcome Survey Form-36 (higher score indicates better health status); FEV1 = forced expired volume in one second; MRC = 
Medical Research Council functional dyspnoea; *p < 0.05; **p < 0.01, Spearman's rank correlation.
Correlation between CCQ and FEV1 %predicted in 175  subjects Figure 1
Correlation between CCQ and FEV1 %predicted in 
175 subjects. CCQ = Clinical COPD Questionnaire. FEV1 = 
forced expired volume in one second.
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assumption behind the original English version (range
from -0.20 to -0.4). The correlation was stronger than
expected also in the Italian version, concerning the whole
population study and the COPD population alone.
In addition to the FEV1, also MRC functional dyspnoea
has proved to be useful in predicting outcomes in patients
with COPD, thus MRC functional dyspnoea measurement
is recommended in the routine handling and evaluation
of these patients [1]. In the present study, both MRC score
and CCQ scores values were able to discriminate healthy
subjects and COPD patients with different degree of air-
ways obstruction (from mild-moderate to very severe).
We had the opportunity of testing the correlation between
CCQ scores and MRC score and it was statistically highly
significant.
We found no significant difference, as far as the CCQ
functional state is concerned, between healthy subjects
and mild-moderate patients with COPD. This reflects
COPD guidelines [1], which state that restrictions in daily
living activities only become significantly apparent once
the FEV1 falls below 50% predicted, i.e., as a result of the
transition from mild-moderate to severe airways obstruc-
tion in patients with COPD.
BMI calculation has also proved to be useful in the routine
handling of patients with COPD [1]. In the present study,
BMI does not differ significantly between healthy and
diseased subjects and among groups of COPD patients
with different degrees of airways obstruction. According
to Celli BR et al. [10], BMI <= 21 is associated with poor
prognosis in patients with COPD. Therefore, this
condition can be considered an indication of less than
optimal clinical control in patients with COPD. In our
study, CCQ scores were able to discriminate the patients
with COPD and BMI <= 21 in the COPD population. The
relation between BMI and CCQ scores in our COPD pop-
ulation is non-linear, since scores tend to be worse with
both decreasing BMI values below 22 and increasing val-
ues above 28. This trend, which is statistically significant
only in the low BMI range, explains the non-significant
overall correlation that was found between BMI values
and CCQ scores in patients with COPD. Only the CCQ
mental state score is significantly worse in the overweight
group, compared with the acceptable BMI range group.
This would suggest the presence in these subjects of emo-
tional problems, possibly related also to overfeeding.
We have been able, by means of the CCQ scores, to detect
significant changes in response to the inpatient portion of
a comprehensive and continuous standard pulmonary
rehabilitation program for patients with COPD. Disease
control improvement is also documented with independ-
ent outcome measurements of variables at the end of 6
MWT. It is a well-known fact that improvements in clini-
cal disease control and health status occur with
pulmonary rehabilitation, despite a minimal effect on
pulmonary function measurement, i.e., FEV1 % predicted
[1,7,11]. The present study wishes to validate the Italian
language version of the CCQ questionnaire; it does not
intend to validate the optimal duration of a time-limited
pulmonary rehab program. The GOLD guidelines [2] state
that there is type B scientific evidence for two-month
duration of a time-limited pulmonary rehab program in
patients with COPD. In our clinical practice, we have
never succeeded in obtaining the compliance of patients
with stable COPD over such a long pulmonary rehab hos-
pitalization period.
The comparison of our data with the results presented in
the original CCQ article [3] show similar CCQ scores as
far as the healthy subjects group is concerned (total score
< 1). A separate comparison for severe and very severe
groups of patients with COPD was impossible since the
original CCQ article [3] presents data in these patients,
grouped according to the classification criteria available in
January 2003. Indeed, the classification of patients into
different groups has been changed from one based upon
the relation between airways obstruction and clinical fea-
tures (respiratory failure or clinical signs of heart failure)
[12] into another based upon airways obstruction alone
[1,2]. However, we excluded from the study the patients
with signs of heart failure or acute respiratory failure.
Table 4: Changes of CCQ scores in 46 patients submitted to pulmonary rehabilitation
Baseline HospitalR HomeR
CCQ functional state 2.2 (0.5–5.0) 1.5 (0.0–4.7)* 1.7 (0.0–4.7)*
CCQ symptom 1.8 (0.2–4.7) 1.3 (0.0–3.5)* 1.7 (0.0–4.2)*
CCQ mental state 2.0 (0.5–4.0) 1.0 (0.0–3.5)* 1.5 (0.0–4.5)*
CCQ total 2.0 (0.0–3.9) 1.3 (0.0–3.8)* 1.7 (0.0–4.0)*
Distance_walked (m) 264 (104–380) 306 (156–459) -----
Borg end-walking 2 (1–9) 1 (0–8) -----
CCQ = Clinical COPD Questionnaire, HospitalR = end of hospital pulmonary rehabilitation, HomeR = during home rehabilitation. Borg = 
breathlessness rating scale. *p < 0.05 after Wilcoxon U test (HospitalR or HomeR versus Baseline)Publish with BioMed Central    and   every 
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In our study, a separate comparison between mild and
moderate COPD was impossible, since patients with mild
COPD seldom refer to our specialized outpatient clinic.
Furthermore, in our clinical setting, we have been unable
to find any subject presenting symptoms of COPD in the
absence of airways obstruction (subjects who risk devel-
oping COPD). We believe such patients are more typical
in a general practice setting, as is the case in the original
CCQ development and validation study [3].
Conclusions
The clinical COPD questionnaire is the first to have been
specifically developed and validated to measure clinical
control in patients with COPD in general practice [3]. The
validation of the questionnaire, in Italian and in specific
pulmonary disease clinical practice, confirms strong dis-
criminative properties, test-retest reliability and respon-
siveness. Furthermore, the CCQ scores are highly
correlated with the usual functional dyspnoea MRC scale
and are able to discriminate COPD patients with already
known poor prognosis according to the critical BMI index.
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